Market Overview:
The global advanced renal cell carcinoma therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of renal cell carcinoma, rising awareness about advanced renal cell carcinoma therapies, and technological advancements in the field of cancer treatment. Based on type, the global advanced renal cell carcinoma therapeutics market is segmented into radiation therapy, chemotherapy, hormone therapy, and investigational therapy. Radiation therapy is expected to account for the largest share of the global advanced renal cell carcinoma therapeutics market in 2018 owing to its high efficacy in treating various types of cancer including renal cell carcinoma. Chemotherapy is also expected to witness significant growth during the forecast period due to its ability to effectively treat various types of cancers including metastatic tumors. Based on application, hospitals are estimated to account for the largest share of the global advanced renal cell carcinoma therapeutics market in 2018 followed by cancer research institutes and ambulatory surgical centers.
Product Definition:
Advanced renal cell carcinoma therapeutics is the term used to describe the latest and most advanced treatments for renal cell carcinoma. These therapies are still in development, but offer hope for those with this type of cancer. The importance of advanced renal cell carcinoma therapeutics is that they may offer a better chance at long-term survival for those with this type of cancer.
Radiation Therapy:
Radiation therapy is a treatment that uses high energy rays or particles to destroy cancer cells. Radiation oncology is used in the treatment and diagnosis of cancer. The types of cancers that are treated with radiation oncology include skin, lung, breast, prostate and other types of cancers. There are different ways by which radiation can be administered such as external beam radiation therapy (EBRT), intraoperative radiotherapy (IORT), radioisotope therapy (RIT) etc.
Chemotherapy:
Chemotherapy is the use of drugs or chemical substances to treat cancer. Chemotherapy may be used with surgery, radiation therapy, or immunotherapy. The most common types of chemotherapies used are alkylating agents (such as busulfan), cytotoxic agents (such as carmustine), antimetabolites (such as 5-fluorouracil), and plant derivatives (toxins such as taxotere).
Global chemotherapy.
Application Insights:
The others segment held the largest share of revenue in 2017. This can be attributed to the availability of advanced therapies for other applications, such as kidney cancer treatment at outpatient facilities and home healthcare. In addition, an increase in incidence rates of ERCs has led to a rise in demand for these drugs across the globe.
Hospitals were estimated to be the fastest-growing application segment owing to increasing awareness about early diagnosis and availability of high-quality care services at hospitals. Furthermore, hospitals are equipped with highly sophisticated equipment that allows Renal Cell Carcinoma (RCC) patients access to treatments that would have been inaccessible had they remained at home without medical assistance or treatment centers. These factors are anticipated to drive growth over the forecast period (see table below).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a well-established healthcare infrastructure, high adoption of advanced therapeutics, and favorable reimbursement scenario. In addition, increasing R&D investments by major pharmaceutical companies is expected to drive growth during the forecast period. Asia Pacific is estimated to witness lucrative growth over the coming years owing to rising disposable income and improving healthcare facilities in emerging countries such as China and India.
Major players operating in this space include but are not limited to: AbbVie Inc.; AstraZeneca; Bristol-Myers Squibb Company; Pfizer Inc.; Merck Group; Celgene Corporation; New York -based ImmunoGen Inc.; Seattle Genetics LLC.
Growth Factors:
- Increasing incidence of renal cell carcinoma (RCC)
- Growing demand for better and more efficacious therapies for advanced RCC
- Rising awareness about advanced RCC and its treatment options
- Availability of novel targeted therapies and immunotherapies for the treatment of advanced RCC
- increasing investment in research and development for the advancement of treatments for advanced RCC
Scope Of The Report
Report Attributes
Report Details
Report Title
Advanced Renal Cell Carcinoma Therapeutics Market Research Report
By Type
Radiation Therapy, Chemotherapy, Hormone Therapy, Investigational Therapy
By Application
Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Others
By Companies
Acceleron Pharma, Argos Therapeutics, AVEO Pharmaceuticals, Bayer, Bristol-Myers Squibb Company, Eisai, Exelixi, Genentech, Immatics Biotechnologies, Merck, Novartis, Ono Pharmaceutical, Pfizer, Rexahn Pharmaceuticals, Hoffmann-La Roche
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
218
Number of Tables & Figures
153
Customization Available
Yes, the report can be customized as per your need.
Global Advanced Renal Cell Carcinoma Therapeutics Market Report Segments:
The global Advanced Renal Cell Carcinoma Therapeutics market is segmented on the basis of:
Types
Radiation Therapy, Chemotherapy, Hormone Therapy, Investigational Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Acceleron Pharma
- Argos Therapeutics
- AVEO Pharmaceuticals
- Bayer
- Bristol-Myers Squibb Company
- Eisai
- Exelixi
- Genentech
- Immatics Biotechnologies
- Merck
- Novartis
- Ono Pharmaceutical
- Pfizer
- Rexahn Pharmaceuticals
- Hoffmann-La Roche
Highlights of The Advanced Renal Cell Carcinoma Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Radiation Therapy
- Chemotherapy
- Hormone Therapy
- Investigational Therapy
- By Application:
- Hospitals
- Cancer Research Institutes
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Advanced Renal Cell Carcinoma Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Advanced renal cell carcinoma (ARC) is a type of cancer that develops in the kidneys. It is the most common form of kidney cancer, and it can be deadly if not treated quickly. There are many different types of treatments available for ARC, but only a few are approved by the FDA for use in people with this disease. Advanced renal cell carcinoma therapies include surgery, radiation therapy, and chemotherapy.
Some of the key players operating in the advanced renal cell carcinoma therapeutics market are Acceleron Pharma, Argos Therapeutics, AVEO Pharmaceuticals, Bayer, Bristol-Myers Squibb Company, Eisai, Exelixi, Genentech, Immatics Biotechnologies, Merck, Novartis, Ono Pharmaceutical, Pfizer, Rexahn Pharmaceuticals, Hoffmann-La Roche.
The advanced renal cell carcinoma therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Advanced Renal Cell Carcinoma Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Advanced Renal Cell Carcinoma Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Advanced Renal Cell Carcinoma Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Advanced Renal Cell Carcinoma Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Advanced Renal Cell Carcinoma Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Advanced Renal Cell Carcinoma Therapeutics Market Size and Y-o-Y Growth
4.5.2 Advanced Renal Cell Carcinoma Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Advanced Renal Cell Carcinoma Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Type
5.2.1 Radiation Therapy
5.2.2 Chemotherapy
5.2.3 Hormone Therapy
5.2.4 Investigational Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Advanced Renal Cell Carcinoma Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Cancer Research Institutes
6.2.3 Ambulatory Surgical Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Advanced Renal Cell Carcinoma Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Advanced Renal Cell Carcinoma Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Type
9.6.1 Radiation Therapy
9.6.2 Chemotherapy
9.6.3 Hormone Therapy
9.6.4 Investigational Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Cancer Research Institutes
9.10.3 Ambulatory Surgical Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Advanced Renal Cell Carcinoma Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Type
10.6.1 Radiation Therapy
10.6.2 Chemotherapy
10.6.3 Hormone Therapy
10.6.4 Investigational Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Cancer Research Institutes
10.10.3 Ambulatory Surgical Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Advanced Renal Cell Carcinoma Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Type
11.6.1 Radiation Therapy
11.6.2 Chemotherapy
11.6.3 Hormone Therapy
11.6.4 Investigational Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Cancer Research Institutes
11.10.3 Ambulatory Surgical Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Advanced Renal Cell Carcinoma Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Type
12.6.1 Radiation Therapy
12.6.2 Chemotherapy
12.6.3 Hormone Therapy
12.6.4 Investigational Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Cancer Research Institutes
12.10.3 Ambulatory Surgical Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Advanced Renal Cell Carcinoma Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Type
13.6.1 Radiation Therapy
13.6.2 Chemotherapy
13.6.3 Hormone Therapy
13.6.4 Investigational Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Advanced Renal Cell Carcinoma Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Cancer Research Institutes
13.10.3 Ambulatory Surgical Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Advanced Renal Cell Carcinoma Therapeutics Market: Competitive Dashboard
14.2 Global Advanced Renal Cell Carcinoma Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Acceleron Pharma
14.3.2 Argos Therapeutics
14.3.3 AVEO Pharmaceuticals
14.3.4 Bayer
14.3.5 Bristol-Myers Squibb Company
14.3.6 Eisai
14.3.7 Exelixi
14.3.8 Genentech
14.3.9 Immatics Biotechnologies
14.3.10 Merck
14.3.11 Novartis
14.3.12 Ono Pharmaceutical
14.3.13 Pfizer
14.3.14 Rexahn Pharmaceuticals
14.3.15 Hoffmann-La Roche
